Navigation Links
FFF Enterprises Selects A10 Networks' AX Series Advanced Traffic Manager
Date:4/25/2008

AX Series Delivers MyFluVaccine Portal a Next-generation Server Load

Balancer Platform for Web Application Delivery

SAN JOSE, Calif., April 25 /PRNewswire/ -- A10 Networks(R) today announced that FFF Enterprises, the nation's largest distributor of plasma products, vaccines and other biopharmaceuticals, selected and deployed A10's AX Series Advanced Traffic Manager to provide a Web application delivery platform for its MyFluVaccine(TM) portal. MyFluVaccine,(TM) delivered by FFF Enterprises, is the nation's first online vaccine portal, allowing vaccine providers to order a dedicated supply of vaccines for guaranteed delivery on the dates they choose. FFF Enterprises selected A10's AX Series to load balance its Web servers, especially during peak usage conditions, to ensure the MyFluVaccine portal is always available and performing as desired for its customers.

To prepare for the peak flu vaccine ordering season, FFF enterprises began evaluating Juniper's DX line of server load balancers. However, shortly after the initial evaluation, Juniper announced it will end of life its DX family with a smooth transition for customers. FFF Enterprises concurrently read about A10's AX Series Advanced Traffic Manager family in the news, highlighting recent independent third-party performance tests from the Tolly Group, which proved that AX delivers over double the performance at less than half the price of incumbents. As a result, FFF Enterprises chose to evaluate the AX Series.

"We found the AX Series at the perfect time. After reading positive stories about its price/performance advantage over incumbents we tested the AX in our environment and discovered that the claims we read were true," said Bob Coates, VP of Technology for FFF Enterprises. "A10's AX Series provides us with a high-performance server load balancer solution to ensure MyFluVaccine(TM) is always performing and available."

The key AX Series features that FFF Enterprises leverages include Layer 4-7 server load balancing, SSL acceleration/offload to increase Web transaction speed and application persistence to ensure a positive experience for customers placing orders on the portal. FFF Enterprises also leverages AX's high-performance aRule(TM) advanced scripting to customize policies to manipulate Layer 7 traffic and avoid traffic bottlenecks.

Additional key features within the AX Series include:

-- Revolutionary Advanced Core Operating System (ACOS):

-- Leverages modern system architectures

-- Tuned for multiple-core CPUs

-- Industry's best SSL and Layer 4-7 performance, at the most

cost-effective price

-- Carrier-grade hardware components and redundancy

"We are proud to provide FFF Enterprises the superior Web Application Delivery platform it requires while running its industry-leading MyFluVaccine(TM) portal," said Lee Chen, founder and CEO of A10 Networks. "The AX Series achieves high performance in a small footprint that delivers a significant price advantage for the Web Application Delivery market."

Advanced Core Operating System (ACOS): Optimized Multi-CPU Architecture

The Advanced Core Operating System (ACOS) -- built by A10's team of industry-leading engineers with high performance Layer 2-3, Layer 4-7 and super computing expertise -- is the distinguishing technology that makes the AX Series stand out in the Web application delivery market. Many of the incumbent vendors' solutions are based on legacy architecture not designed to address the greater scale of Internet traffic and security requirements -- for today and tomorrow. In order to address the need for speed, vendors continue to move their single-CPU software solutions to more powerful multi-CPU traffic management systems. But without the complete redesign of the software, performance benefits as a result of more powerful hardware will never be realized.

A10's AX Series with ACOS includes an optimized, multi-CPU architecture, built from the ground up. ACOS provides the ability to linearly and concurrently scale processing resources. By evenly distributing application traffic to the system's processors, ACOS eliminates performance bottlenecks caused by unevenly loaded processors -- allowing applications to perform as desired, especially during peak usage conditions.

To read the full case study, please visit: http://www.a10networks.com/resources/files/CS-FFF.pdf

About A10 Networks

A10 Networks was founded in Q4 2004 with a mission to provide innovative networking and security solutions. A10 Networks makes high-performance products that help organizations accelerate, optimize and secure their applications. A10 Networks is headquartered in Silicon Valley with offices in the United States, Japan, China, Korea and Taiwan. For more information, visit http://www.a10networks.com.

About FFF Enterprises

Founded in 1988, FFF Enterprises is a multidimensional healthcare company, delivering innovative solutions in biopharmaceutical management and distribution, managed healthcare services, health information management and consumer healthcare services. FFF's influenza vaccine innovation, MyFluVaccine.com, launched in 2006, revolutionized the influenza vaccine marketplace, allowing healthcare providers to select their influenza vaccine delivery dates -- bringing trust to the marketplace.

For more information about FFF Enterprises and MyFluVaccine, visit http://www.fffenterprises.com or call 800-843-7477.


'/>"/>
SOURCE A10 Networks
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Medsphere & Keane Join Forces to Provide Healthcare Enterprises With Integrated Electronic Health Record & Revenue Cycle Management Systems
2. Dr. Andrew K. Palmer Joins BMEs (BioMedical Enterprises, Inc.) Board of Directors
3. BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the OSSArc(TM) Anatomic Residual Compression Implant
4. Varian Medical Systems Acquires Pan-Pacific Enterprises for Marketing, Sales and Distribution of X-Ray Imaging Products in China
5. CJPS Enterprises Spins Off New Company for Intellectual Property Marketing
6. Nu Skin Enterprises Announces Increase in Quarterly Dividend
7. Harris Corporation Demonstrates Digital Signage(TM) Solutions for Dynamic, Rapid Communications within Healthcare Enterprises
8. Nu Skin Enterprises to Present at Bank of America 2008 Consumer Conference
9. CJPS Enterprises to Expand Efforts of 21st Century Jobs Fund Life Sciences Pipeline
10. Nu Skin Enterprises to Announce First Quarter 2008 Results
11. CJPS Enterprises Announces a Series of Seminars on Automotive Diversification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... edition of "Cardiovascular Health" in USA Today, which covers the innovative treatments, therapeutic ... health while maintaining fulfilling lives. “We are prolonging life 6 years in the ...
(Date:12/2/2016)... ... 2016 , ... Sourced from the Isbre Springs beneath the 5,000 year old ... purity of just 6 ppm TDS (Total Dissolved Solids) in addition to its excellent ... in several ShopRite and FoodTown stores in NJ and received rave comments from consumers. ...
(Date:12/2/2016)... San Francisco, CA (PRWEB) , ... December 02, ... ... in digitally-enabled care journeys, announced today that it has raised $6.0 million in ... are inspired by Clarify Health’s conviction that patients and their caregivers can receive ...
(Date:12/2/2016)... ... 2016 , ... ‘Tis the season for giving! Today, 20 creative teams across ... Partnership and the Drug Enforcement Administration as part of the National Red Ribbon Week ... schools who decorated their campuses with this year’s Red Ribbon Week theme: “YOLO. Be ...
(Date:11/30/2016)... ... 30, 2016 , ... Standard Process, Inc. is proud to ... recognition of the largest closely held companies headquartered in Wisconsin. This marks the ... Standard Process was awarded the Talent Award for providing outstanding employee benefits. ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , December 2, 2016 ... "In Vitro Diagnostics/IVD Market by Product (Instruments, Reagents, ... Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) - ... market is valued at USD 60.22 Billion in ... a CAGR of 5.5% during the forecast period ...
(Date:12/2/2016)... 2, 2016 On Thursday, December ... excellence in research, development and innovation in the biopharmaceutical ... was held in the presence of Sergey Tsyb, Vice ... Russian Federation , Natalia Sanina, First Vice Chairman ... , Head of Roszdravnadzor, National Service of Control in ...
(Date:12/2/2016)... -- bioLytical Laboratories, ein Weltführer bei schnellen Tests für Infektionskrankheiten, ... von Kenia eingeführt. Continue Reading ... ... (PRNewsFoto/bioLytical Laboratories) ... http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical wurde durch die Clinton ...
Breaking Medicine Technology: